Introduction
Actinium-225 DOTATATE therapy (Ac-225 DOTATATE) is an advanced form of alpha-particle peptide receptor radionuclide therapy (PRRT) used for selected patients with neuroendocrine tumors (NETs).
It is designed for cases where disease is aggressive, advanced, or resistant to standard treatments, including beta-emitting PRRT such as Lutetium-177 DOTATATE.
This therapy targets somatostatin receptors, which are highly expressed on many well-differentiated neuroendocrine tumors.
Actinium-225 emits high-energy alpha particles with an extremely short tissue range, allowing highly precise tumor cell destruction while limiting radiation exposure to surrounding healthy tissue.
Türkiye is a trusted destination for advanced nuclear medicine therapies, offering experienced specialists, modern treatment facilities, and integrated neuroendocrine oncology care.
Averia Health supports international patients through ethical, structured, and fully coordinated Actinium-225 DOTATATE therapy focused on safety, precision, and continuity of care.
Why Choose Türkiye for Actinium-225 DOTATATE Therapy
Türkiye is internationally recognized for advanced neuroendocrine tumor treatment because of:
- Experienced nuclear medicine physicians and NET specialists
- Availability of alpha-particle radionuclide therapies in specialized centers
- Advanced nuclear medicine treatment units
- Multidisciplinary neuroendocrine tumor boards
- Strict radiation safety and quality assurance protocols
- Internationally accredited hospitals
Türkiye combines next-generation targeted therapy with comprehensive oncologic expertise.
Why Choose Averia Health
Averia Health provides structured coordination for Actinium-225 DOTATATE therapy:
- Pre-arrival review of medical history, pathology, and prior treatments
- Coordination of DOTATATE PET-CT eligibility assessment
- Referral to experienced alpha-PRRT treatment centers
- Multidisciplinary coordination (oncology, endocrinology, nuclear medicine)
- Clear explanation of therapy goals, benefits, and limitations
- Professional interpreter services
- 24/7 patient support during your stay
- Post-therapy follow-up and international care coordination
Our approach prioritizes ethical practice, patient safety, and informed decision-making.
Who Is a Candidate for Actinium-225 DOTATATE Therapy
Actinium-225 DOTATATE therapy may be considered for patients with:
- Well-differentiated neuroendocrine tumors
- Advanced, metastatic, or inoperable NETs
- Somatostatin receptor–positive disease confirmed on DOTATATE PET-CT
- Disease progression after Lutetium-177 DOTATATE or other systemic therapies
- Adequate kidney, liver, and bone marrow function
Final eligibility is determined through comprehensive specialist evaluation.
Diagnostic Evaluation Before Therapy
Before treatment, patients typically undergo:
- DOTATATE PET-CT to confirm somatostatin receptor expression
- Blood tests to assess kidney, liver, and bone marrow reserve
- Review of tumor grade, pathology, and disease progression
- Oncology and nuclear medicine consultations
- Evaluation of prior PRRT response and overall health status
Careful patient selection is essential due to the potency of alpha therapy.
Actinium-225 DOTATATE Therapy Procedure
Radioligand Administration
Actinium-225 DOTATATE is administered intravenously in a controlled nuclear medicine setting.
Alpha-Particle Targeted Therapy
The radioligand binds to somatostatin receptors on tumor cells and delivers high-energy alpha radiation that causes irreversible DNA damage.
Organ Protection and Monitoring
Protective protocols are applied, particularly for kidneys and bone marrow, with close clinical and laboratory monitoring.
Treatment is performed by experienced teams following strict international safety standards.
Treatment Journey in Türkiye
- Pre-Arrival Case Review
Medical records, imaging, and laboratory results are evaluated. - Eligibility Confirmation
DOTATATE PET-CT and clinical criteria confirm suitability. - Personalized Treatment Planning
Therapy strategy, expectations, and precautions are explained clearly. - Actinium-225 DOTATATE Therapy
Treatment is administered in a specialized nuclear medicine unit. - Post-Therapy Care & Monitoring
Side effects, blood counts, and organ function are closely monitored. - Follow-Up & Long-Term Care Coordination
Ongoing oncologic care and international follow-up are arranged.
Expected Results & Benefits
- Highly targeted treatment of somatostatin receptor–positive NETs
- Potential disease control in advanced or treatment-resistant cases
- Tumor cell destruction at the microscopic level
- Option for patients with limited remaining systemic therapies
- Precision targeting with minimal radiation to surrounding tissue
Response varies depending on tumor biology, disease burden, and prior treatments.
Risks & Considerations
Actinium-225 DOTATATE therapy is a potent treatment and may involve:
- Fatigue
- Temporary bone marrow suppression
- Kidney function changes requiring monitoring
- Nausea or mild gastrointestinal discomfort
- Need for careful dosing and follow-up
All potential risks are explained thoroughly before treatment.
What’s Included in Your Medical Trip
- Pre-therapy consultations and eligibility evaluation
- DOTATATE PET-CT coordination (if required)
- Actinium-225 DOTATATE therapy
- Nuclear medicine and hospital services
- Organ protection measures and post-therapy monitoring
- Interpreter services
- 24/7 patient support
- International oncology follow-up coordination
Averia Health ensures ethical, precise, and patient-centered alpha-PRRT care.
Frequently Asked Questions
How is Actinium-225 DOTATATE different from Lutetium-177 DOTATATE?
Actinium-225 emits alpha particles, which are more potent and shorter-range than beta radiation from Lutetium-177.
Is this therapy chemotherapy?
No. It is a targeted alpha-radionuclide therapy (PRRT), not chemotherapy.
Who is this treatment best suited for?
Patients with advanced, somatostatin receptor–positive NETs, often after other therapies.
Is the treatment safe?
Yes, when performed in specialized centers with strict monitoring.
Can follow-up care continue after returning home?
Yes. International follow-up and coordination are provided.
Ready to Start Your Health Journey?
Access next-generation targeted treatment for neuroendocrine tumors with Actinium-225 DOTATATE therapy in Türkiye.
Request a free quote or contact us on WhatsApp to speak with our neuroendocrine oncology coordination team.
